TNFRSF9 and neoplasm: Treatment of tumor-bearing immunocompromised Rag(-/-) mice with agonist CD137 monoclonal antibody not only enhances T cell activation but also stimulates tumor-associated ECs augmenting cell surface expression of ICAM-1, VCAM-1, and E-selectin with consequent promotion of CD8+ T cell recruitment into the malignant tissue (224).